EPI E Z PEN JR (epinephrine) by Viatris (2) is adrenergic alpha-agonists [moa]. First approved in 1987.
Drug data last refreshed 14m ago · AI intelligence enriched 1w ago
EPI E Z PEN JR is an epinephrine auto-injector administered intramuscularly for emergency treatment of anaphylaxis and acute allergic reactions in pediatric patients. It works as an alpha-adrenergic agonist, rapidly reversing airway constriction, hypotension, and other life-threatening symptoms of severe allergic reactions.
Approaching loss of exclusivity with moderate competitive pressure (30/100) signals potential team downsizing and shift to generic defense or lifecycle extension strategies.
Adrenergic alpha-Agonists
alpha-Adrenergic Agonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Continuous Versus Bolus Norepinephrine Administration to Treat Postinduction Hypotension
Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias
Hemodynamic Effects of Norepinephrine Reduction on Critical Closing Pressure in Distributive Shock
Pneumatic Leg Compression and Norepinephrine Requirements in Patients Having Non-cardiac Surgery
Treating Intraoperative Bradycardia in Non-cardiac Surgery Patients With Atropine at Heart Rates Below 60 Versus 30 Beats Per Minute and Norepinephrine Requirements
Worked on EPI E Z PEN JR at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on EPI E Z PEN JR as LOE approaches offers limited growth trajectory but valuable experience in defensive brand strategy, generic competition management, and pediatric market access. Career development is best suited for professionals seeking to deepen expertise in established product maintenance and market share protection rather than new product launches.